Peregrine flying high as CMO biz preps to open new mAb facility
Avid Bioservices' expansion will double existing capacity to service both a $40m backlog and its owner Peregrine, which is hoping to commercialise its breast cancer candidate.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs